NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, ...